When a pharma visual aid goes through three or four revision rounds between the brand team and the designer, the easy assumption is that the designer is not getting the creative right. The layout keeps feeling off. The call-outs are in the wrong place. The colours do not quite match the brand. So the team keeps going back and forth until the design lands.
That is the assumption. It is also, in my experience, rarely the real story.
I have watched enough of these revision loops over the years to be confident about what actually drives them. The design work itself is usually not the issue. The designer knows how to lay out a page, how to balance a visual hierarchy, how to use whitespace. What the designer does not have, and cannot be expected to have, is the specific judgement that sits inside the brand team’s head.
Where the Judgement Really Sits
A brand manager reads a visual aid through a filter built from years of watching MRs in the field, reading internal review comments, talking to medical teams, absorbing competitor materials. That filter catches, almost without any conscious effort, that the efficacy claim on page two needs a stronger reference, that the image on page four feels borrowed from a Western campaign and will not resonate with an Indian doctor, that the call to action on page five is too soft for this therapy area.
The brand manager writes these thoughts in an email. Or shares them on a call. Or scribbles them on a printout and sends a photo.
The designer receives the feedback and interprets as best possible. Some of it is clear. Some of it is not. The designer makes the changes that were understood, sends the next version back, and waits.
The brand manager opens the new version and sees that two out of five changes are as requested. One was misunderstood. Two others the designer caught in another way, slightly different from what the brand manager had in mind. A new email gets written. And the loop continues.
This is the revision cycle that drains three weeks out of a collateral timeline. It is not about design skill. It is about the quality of the handoff from brand to designer.
What the Designer Actually Wants
Here is what I find interesting. If you ask a good designer what they want from a brand manager, the answer is almost never more creative freedom. The answer is almost always more specificity. Tell me exactly what to change on which element on which page and I will do it. Tell me the reason behind the change so I can apply the same thinking elsewhere. Tell me which of these is a must have and which is a nice to have so I can prioritise. That is what most designers actually want.
What the Brand Manager Actually Wants
And if you ask a brand manager what they want from a designer, the answer is almost never more creative ideas. The brand manager wants the changes already identified to land in one round, not three. This is not about being a micromanager. This is about avoiding a fortnight of small misalignments adding up into a delayed launch.
Both sides want the same thing. A cleaner handoff.
Yet the handoff, in most pharma brand teams I have worked with, is a free text email. Sometimes a shared document. Rarely a structured list of changes with the finding, the recommended fix, the reason, and the priority, organised page by page and element by element.
The reason is not that brand managers do not know how to write a structured list. It is that writing one takes time. And time is always the binding constraint for a brand manager. So the email gets written quickly, the designer interprets as best possible, and the loop begins.
What Actually Changes the Pattern
What changes the pattern is not more creative meetings or better chemistry between the brand team and the design team. Both of those help at the margin. What changes the pattern is having a structured document that captures all the changes in one place, page by page, with enough specificity that the designer can execute without coming back for clarification.
This is worth saying out loud because most brand teams have never seen what a clean handoff document looks like. They have seen briefs. They have seen creative inputs. They have seen feedback emails. What they have not seen is a document that takes the brand team’s considered review of a finished collateral and converts it into a designer ready instruction set. When a team sees that document for the first time, the reaction is usually some version of “this should have existed all along.”
It should have. The discipline of writing such a document has existed for decades in other industries. What was missing in pharma was not capability. It was the realisation that the revision loop problem was a handoff problem, not a design problem.
The Simpler Fix
Once you see it that way, the fix is obvious. Build one structured document per collateral that captures every accepted change, each with the page number, the element, the recommended fix, the reason, and the priority. Hand that document to the designer along with the collateral file. Let the designer work from the document, not from a series of emails.
A designer working from a clean document will take one round to deliver the same work that would have taken four rounds through email. The brand manager gets time back. The designer gets respect back. And the collateral reaches the field a fortnight earlier than it otherwise would.
Most revision cycles on a pharma collateral are not really about the design. They are about the quality of what the designer was asked to change. Fix the handoff, and most of the loop quietly disappears.